ArticlePharmaceutical science advances2025
D-pinitol modulates the anti-emetic effects of aprepitant, domperidone, and ondansetron in chicks.
Article in Pharmaceutical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In Vivo Evaluation of Psoralen in a Copper Sulfate-Induced Chick (Gallus gallus domesticus) Emesis Model and In Silico Analysis of Its Interaction With DChemistryOpen · 2026Article
- AlkaPlorer: A database-driven explorer for natural alkaloids and derivatives.Journal of integrative plant biology · 2026Article
- Research progress of blood-brain barrier penetrating and brain diseases therapy by natural biopolymer - based nanomedicine delivery systems.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naturally occurring substance, D-pinitol (DPL) belongs to the significant inositol family has numerous pharmacological activity. In this study we evaluated the anti-emetic effect as well as modulation activities of DPL on the recent market drugs aprepitant (APR), domperidone (DOM), hyoscine butyl bromide (HYS), and ondansetron (ODN) on emesis in the chick model. To highlight the possible anti-emetic activity in copper sulfate induced emesis chick models, we use several reference drugs, such as APR (26 mg/kg), DOM (7 mg/kg), OND (5 mg/kg), and HYS (21 mg/kg), as positive controls, while the vehicles serve as negative controls. All reference drugs are given alone or in combined groups to evaluate their anti-emetic and modulation effects. The results suggest DPL (25 or 50 mg/kg) increases the mean number of latency in the chicks compared to vehicles, and the combination groups, DPL (25 mg/kg) showed better anti-emetic effects with DOM and ODN while DPL (50 mg/kg) reduces the number of retches compared to vehicles and combined drug therapy with reference drugs. Additionally, A variety of computational algorithms were used to visualise ligand-receptor interactions and quantify the binding affinities of DPL and other ligands towards the dopamine receptors (D2 and D3), muscarinic acetylcholine receptors (M1-M5), and serotonin receptor (5HT3). The molecular docking study indicated that DPL exhibits the highest binding affinity towards subtypes M2 (having a docking score of -5.7 kcal/mol) and D3 (having a docking score of -5.7 kcal/mol) in comparison to certain standards for these receptors, which have docking scores of DOM (-9.7 kcal/mol) and HYS (-7.1 kcal/mol) for M2 and D3, respectively. Our findings suggest that DPL has anti-emetic properties in chicks, possibly through interactions with the M2 and D3 receptor pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.